Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Sep 1;59(9):2392-2401.
doi: 10.1093/rheumatology/kez590.

MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis

Anouk M Barendregt  1   2 , Saskia R Veldkamp  1 , Petra C E Hissink Muller  3 , Annemarie van de Geer  4 , Cathelijn Aarts  4 , E Charlotte van Gulik  1   2 , Marco W Schilham  3 , Christoph Kessel  5 , Mischa P Keizer  4 , Robert Hemke  2 , Amara Nassar-Sheikh Rashid  1 , Koert M Dolman  6   7 , Dieneke Schonenberg-Meinema  1 , Rebecca Ten Cate  3 , J Merlijn van den Berg  1 , Mario Maas  2 , Taco W Kuijpers  1   4
Affiliations
Multicenter Study

MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis

Anouk M Barendregt et al. Rheumatology (Oxford). .

Abstract

Objective: To study two neutrophil activation markers, myeloid-related protein (MRP) 8/14 and neutrophil elastase (NE), for their ability to predict treatment response and flare in patients with JIA.

Methods: Using samples from two cohorts (I and II), we determined MRP8/14 and NE levels of 32 (I) and 81 (II) patients with new-onset, DMARD-naïve arthritis and compared patients who responded to treatment (defined as fulfilling ≥ adjusted ACRpedi50 response and/or inactive disease) with non-responders (defined as fulfilling < adjusted ACRpedi50 response and/or active disease) at 6 and 12 months. Secondly, we compared biomarker levels of 54 (I) and 34 (II) patients with clinically inactive disease who did or did not suffer from a flare of arthritis after 6 or 12 months. Receiver operating characteristic analyses were carried out to study the predictive value of MRP8/14 and NE for treatment response and flare.

Results: For both cohorts, baseline MRP8/14 and NE levels for patients who did or did not respond to treatment were not different. Also, MRP8/14 and NE levels were not different in patients who did or did not flare. Receiver operating characteristic analysis of MRP8/14 and NE demonstrated areas under the curve <0.7 in both cohorts.

Conclusion: In our cohorts, MRP8/14 and NE could not predict treatment response. Also, when patients had inactive disease, neither marker could predict flares.

Keywords: MRP8/14; S100A8/A9; biomarkers; calprotectin; disease activity; flare; juvenile idiopathic arthritis; neutrophil elastase; prediction; treatment response.

PubMed Disclaimer

Figures

<sc>Fig</sc>. 1
Fig. 1
Dot plots of MRP8/14 levels in cohort I for the primary outcomes (A) Treatment response after 6 months. (B) Treatment response after 12 months. (C) Active vs inactive disease after 6 months. (D) Active vs inactive disease after 12 months. (E) Occurrence of a flare within 6 months. (F) Occurrence of a flare within 12 months.
<sc>Fig</sc>. 2
Fig. 2
Dot plots of MRP8/14 levels in cohort II for treatment response (A) Treatment response after 6 months. (B) Active vs inactive disease after 6 months. (C) Adjusted ACRpedi30/50/70/90/100 responses after 6 months. (D) Treatment response after 12 months. (E) Active vs inactive disease after 12 months. (F) Adjusted ACRpedi30/50/70/90/100 responses after 12 months.
Fig. 3
Fig. 3
Dot plots of MRP8/14 and NE levels in cohort II for flare prediction (A) MRP8/14, occurrence of a flare within 6 months. (B) MRP8/14, occurrence of a flare within 12 months. (C) NE, occurrence of a flare within 6 months. (D) NE, occurrence of a flare within 12 months. NE: neutrophil elastase.
<sc>Fig</sc>. 4
Fig. 4
Dot plots of NE levels in cohort I for the primary outcomes (A) Treatment response after 6 months. (B) Treatment response after 12 months. (C) Active vs inactive disease after 6 months. (D) Active vs inactive disease after 12 months. (E) Occurrence of a flare within 6 months. (F) Occurrence of a flare within 12 months. NE: neutrophil elastase.
<sc>Fig</sc>. 5
Fig. 5
Dot plots of NE levels in cohort II for treatment response (A) Treatment response after 6 months. (B) Active vs inactive disease after 6 months. (C) Adjusted ACRpedi30/50/70/90/100 responses after 6 months. (D) Treatment response after 12 months. (E) Active vs inactive disease after 12 months. (F) Adjusted ACRpedi30/50/70/90/100 responses after 12 months. NE: neutrophil elastase.
See this image and copyright information in PMC

References

    1. Thierry S, Fautrel B, Lemelle I, Guillemin F.. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine 2014;81:112–7. - PubMed
    1. Guzman J, Oen K, Tucker LB. et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015;74:1854–60. - PubMed
    1. Bulatović M, Heijstek MW, Van Dijkhuizen EH. et al. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis 2012;71:1484–9. - PubMed
    1. Aquilani A, Marafon DP, Marasco E. et al. Predictors of flare following etanercept withdrawal in patients with rheumatoid factor-negative juvenile idiopathic arthritis who reached remission while taking medication. J Rheumatol 2018;45:956–61. - PubMed
    1. Moncrieffe H, Ursu S, Holzinger D. et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford) 2013;52:1467–76. - PubMed

Publication types

MeSH terms